1. In Vivo
  2. >>Growth

Gene Therapy: What To Expect Now And In The Future

A Look At The State Of The Industry

 
• By Alaric DeArment

The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.

GeneTherapy
• Source: Shutterstock

A trickle becoming a stream might describe the state of gene therapy development in the US, where in the year 2023 regulators anticipate approving as many gene therapies as they had from 2017-2022. In the process, the US Food and Drug Administration will have unleashed not only viral vector-based gene therapies for ultra-rare diseases, but treatments using newer modalities, like gene editing, to treat more common conditions like sickle cell disease (SCD).

The most recent addition to the armamentarium is BioMarin Pharmaceutical Inc.’s Roctavian (valoctocogene roxaparvovec), which the FDA approved for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.